Navigation Links
American Cancer Society recommends informed decision making in lung cancer screening
Date:1/11/2013

ew guidelines, the authors say: "Findings from the National Cancer Institute's National Lung Screening Trial established that lung cancer mortality in specific high-risk groups can be reduced by annual screening with low-dose computed tomography. These findings indicate that the adoption of lung cancer screening could save many lives."

They conclude: "At this time, there is sufficient evidence to support screening provided that the patient has undergone a thorough discussion of the benefits, limitations, and risks, and can be screened in a setting with experience in lung cancer screening."

But they caution that more work is needed to fill in existing knowledge gaps related to broadening eligibility for lung cancer screening, to further define early lung cancer detection protocols, and to put in place an infrastructure to support population-based lung cancer screening. "As with other guidelines for cancer screening, we can expect that this initial guideline will be revised as new data become available," write the authors.

As with other cancer screening recommendations, the new lung cancer screening guidance embraces the process of informed and shared decision-making; a thoughtful discussion with a clinician related to the potential benefits, limitations, and harms associated with screening. This discussion should occur before any decision is made to initiate lung cancer screening.

Among the limitations and harms posed by screening are missed cancers, anxiety associated with abnormal results, the need for additional imaging tests and biopsies, investigation of incidental findings not related to the lungs, and exposure to radiation from repeated tests.

The recommendations emphasize that smoking cessation counseling remains a high priority for clinical attention in discussions with current smokers, and that screening should not be viewed as an alternative to smoking cessation.

The hope is that the guideline will lea
'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
2. COLA to offer lab quality program to American College of Physicians
3. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association for Hand Surgery 2013 Annual Meeting
4. Americans Suffer Worse Health Than Peers in Other Countries
5. Majority of Americans say new Congress should take immediate action to expand medical research
6. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
7. American Crane's Website Now Includes 3D Models!
8. New American Chemical Society video series: Conversations with Celebrated Scientists
9. Experts Challenge Americans to Reduce Salt Intake
10. Many Americans Drive While Drowsy: Report
11. Worldwide Power Products Launches Agent Program to Reach International Customers; Hires Director of Latin American Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 The family foundation of ... the Mesothelioma Applied Research Foundation (Meso Foundation), half of ... Patient Travel Grant Program . The focus area ... create grant partnerships with organizations that can generate transformational ... Schulze is the founder and chairman emeritus of Best ...
(Date:11/26/2014)... 26, 2014 German scientists say carbon-based ... can cause mesothelioma that looks and acts similar to ... article on the research. Click here to read ... for Toxicology and Experimental Medicine in Hannover injected 500 ... of the rats eventually developed mesothelioma , how ...
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... For those with a New Year’s resolution to get ... at the University of Colorado Anschutz Health and Wellness ... The 45- 60 minute classes have just started and are ... club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition ... at fast results , By focusing on low weight ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... ATLANTA, Sept. 8 Craneware, Inc. (AIM: CRW.L), a leader in sustainable financial improvement ... ended June 30, 2009. , , Financial Highlights , ... in the year totaling $43.2m (FY08: $25.7m), 68% up from the previous year, contributing ... to $23.0m (FY08: $18.7m) , 51% ...
... , , WASHINGTON, Sept. 8 More ... in scrubs and lab coats this week to bring an angry message ... The doctors, all traveling as individuals and at their own expense, will ... meet with the doctors of Congress, including Tom Price, M.D. (GA) and ...
... , , , ... and Walmart,s Leslie Dach to discuss areas of bipartisan agreement in ... The Bipartisan Policy Center (BPC) and Better Health Care Together ... agreement among political, business and labor leaders in the health reform ...
... maintained in mice given HDAC inhibitors, study finds , TUESDAY, ... cancer drug might be able to restore day-to-day memory ... common form of dementia among the elderly, is expected to ... sign is loss of short-term memory. , "People often joke ...
... , BRISTOL, Va. and BIRMINGHAM, Ala., ... (NYSE: HLS ) today announced that a joint venture ... of public need (COPN) to open a new inpatient rehabilitation hospital ... Bristol and throughout Southwest Virginia to have access to comprehensive, high-quality ...
... , NEW YORK, Sept. 8 ... its catalogue. , , Lung Cancer ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , This report ... Millions of US$. The US market for Non-Small Cell Lung Cancer ...
Cached Medicine News:Health News:Craneware Announces Fiscal Year-End Results 2Health News:Craneware Announces Fiscal Year-End Results 3Health News:Dr. 'Smith' Comes to Washington: Angry Physicians From All 50 States Rally in DC on Sept 10 2Health News:Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 3Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 4Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
(Date:11/26/2014)... Nov. 25, 2014 Immune Pharmaceuticals Inc. ... stage biopharmaceutical company that engages in the development ... of inflammatory diseases and cancer, today announced the ... of 3,450,000 units, with each unit consisting of ... value $0.0001 per share, and one warrant to ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company ... purification, today reported that the U.S. Food and Drug Administration has issued ... , , ... final decision letter from the FDA for the company,s 510(k) submission which ...
... July 7 ICAP ... division of ICAP plc (IAP.L), is offering for ... drug formulation technology Captisol® owned by CyDex Pharmaceuticals ... fifteen related foreign counterparts covering two important close-to-market, ...
Cached Medicine Technology:Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 2Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 3Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 4ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc. 2ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc. 3